Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Merck
Mallinckrodt
Colorcon
Federal Trade Commission
McKesson
Johnson and Johnson
Citi
Chinese Patent Office
Express Scripts

Generated: July 22, 2018

DrugPatentWatch Database Preview

Tripelennamine citrate - Generic Drug Details

see a sample report or, see our see our flat-rate plans

« Back to Dashboard

What are the generic drug sources for tripelennamine citrate and what is the scope of tripelennamine citrate freedom to operate?

Tripelennamine citrate
is the generic ingredient in one branded drug marketed by Novartis and is included in one NDA. Additional information is available in the individual branded drug profile pages.

There is one drug master file entry for tripelennamine citrate.
Summary for tripelennamine citrate
US Patents:0
Tradenames:1
Applicants:1
NDAs:1
Drug Master File Entries: 1
Bulk Api Vendors: 6
Patent Applications: 643
DailyMed Link:tripelennamine citrate at DailyMed
Synonyms for tripelennamine citrate
1,2-Ethanediamine, N,N-dimethyl-N'-(phenylmethyl)-N'-2-pyridinyl-, 2-hydroxy-1,2,3-propanetricarboxylate (1:1)
1,2-Ethanediamine, N1,N1-dimethyl-N2-(phenylmethyl)-N2-2-pyridinyl-, 2-hydroxy-1,2,3-propanetricarboxylate (1:1)
2-(Benzyl(2-(dimethylamino)ethyl)amino)pyridine citrate (1:1)
2-hydroxypropane-1,2,3-tricarboxylic acid; N-benzyl-N-[2-(dimethylamino)ethyl]pyridin-2-amine
30OC46A3J9
3B1-006665
6138-56-3
AC1L52TQ
C16H21N3.C6H8O7
CAS-6138-56-3
CCG-39053
CHEMBL1200769
CITRIC ACID; TRIPELENNAMINE
D06246
DSSTox_CID_25989
DSSTox_GSID_45989
DSSTox_RID_81276
DTXSID8045989
EINECS 228-121-6
HE068885
HE362714
HMS2092A14
HMS501K16
LS-130289
N'-benzyl-N,N-dimethyl-N'-pyridin-2-ylethane-1,2-diamine; 2-hydroxypropane-1,2,3-tricarboxylic acid
NCGC00018125-05
NCGC00095775-01
NCGC00095775-02
NSC-757360
NSC757360
PBZ (TN)
Pharmakon1600-01500597
Pyribenzamine citrate
Pyridine, 2-(benzyl(2-(dimethylamino)ethyl)amino)-, citrate (1:1)
SCHEMBL99166
SPECTRUM1500597
Tox21_111518
Tox21_111518_1
Tripelennamine citrate [USAN]
Tripelennamine citrate [USP]
TRIPELENNAMINECITRATE
UNII-30OC46A3J9

US Patents and Regulatory Information for tripelennamine citrate

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Novartis PBZ tripelennamine citrate ELIXIR;ORAL 005914-004 Approved Prior to Jan 1, 1982 DISCN No No ➤ Try a Free Trial ➤ Try a Free Trial ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

see a sample report or, see our see our flat-rate plans

see a sample report or, see our see our flat-rate plans

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Julphar
QuintilesIMS
Cipla
Chubb
US Army
Deloitte
Fish and Richardson
Healthtrust
Accenture

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.